Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 538
Filtrar
2.
BMC Cancer ; 20(1): 1216, 2020 Dec 10.
Artigo em Inglês | MEDLINE | ID: mdl-33302897

RESUMO

BACKGROUND: The prognosis of advanced oral cancer remains dismal. While multimodal therapy is beneficial, maintaining the quality of life of long-term survivors is important. Therefore, risk-adapted treatment regimens need to be designed. We herein investigated whether pathological responses in oral cancer patients treated with preoperative chemoradiotherapy predict locoregional recurrence. METHODS: We retrospectively reviewed the data of 51 oral cancer patients who received preoperative radiotherapy and concurrent pepleomycin, followed by curative surgery at our institution between January 2009 and June 2018. Each patient received preoperative external beam irradiation to the primary tumor and lymphatics (2 Gy per day for approximately 3 weeks) concurrent with pepleomycin (2.5 mg/day). Surgery was performed approximately 3-4 weeks after the completion of preoperative chemoradiotherapy. Pathological responses were defined based on the grading system of Oboshi and Shimosato. RESULTS: Eight, 22, 16, and 5 patients had Oboshi and Shimosato grades 2a, 2b, 3, and 4, respectively. Favorable pathological responses (grades 3 and 4) were observed in 41.2% of patients (21 out of 51 patients). The pathological response and number of pathological lymph node metastases were identified as significant prognostic factors for locoregional control in the univariate analysis. Three-year locoregional control rates were 100 and 56.6% in patients with favorable and unfavorable pathological responses, respectively. CONCLUSIONS: The present study demonstrated that pathological tumor responses to preoperative chemoradiotherapy are a useful predictive factor for locoregional control.


Assuntos
Carcinoma de Células Escamosas/terapia , Quimiorradioterapia , Neoplasias Bucais/terapia , Terapia Neoadjuvante , Peplomicina/uso terapêutico , Radioterapia Conformacional , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Células Escamosas/cirurgia , Quimiorradioterapia/efeitos adversos , Feminino , Seguimentos , Doenças Hematológicas/induzido quimicamente , Humanos , Estimativa de Kaplan-Meier , Irradiação Linfática , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Neoplasias Bucais/cirurgia , Esvaziamento Cervical , Terapia Neoadjuvante/efeitos adversos , Peplomicina/efeitos adversos , Pneumonia Aspirativa/induzido quimicamente , Dosagem Radioterapêutica , Radioterapia Conformacional/efeitos adversos , Estudos Retrospectivos , Resultado do Tratamento , Xerostomia/induzido quimicamente
3.
Int J Oral Maxillofac Surg ; 49(8): 984-992, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-32070653

RESUMO

The objectives of this study were to evaluate survival in 141 patients with stage II-IV oral squamous cell carcinoma (OSCC) treated with preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil (IADCPIVF) via the superficial temporal artery, and to clarify the prognostic factors. The study population included 59 patients with stage II OSCC, 34 with stage III, and 48 with stage IV. After IADCPIVF, 139 patients underwent surgery; minimally invasive surgeries (MIS) including excisional biopsy were performed on 96 patients with a remarkably good response to IADCPIVF. The primary tumour response rate was 99.3% (complete response rate 56.7%, good partial response rate 17.0%, fair partial response rate 25.5%). Additionally, there were no serious adverse events associated with IADCPIVF. The 5-year overall survival rate was 74.6% (stage II 83.6%, stage III 72.7%, stage IV 64.8%). In the multivariate analysis of survival, T classification and clinical tumour response were significant prognostic factors. Eight (8.3%) of the patients who received MIS had primary recurrence and six were salvaged. In conclusion, IADCPIVF is safe and efficacious for treating OSCC, and MIS could reduce the extent of primary tumour resection in the case of a remarkably good response.


Assuntos
Carcinoma de Células Escamosas , Neoplasias Bucais/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica , Cisplatino/uso terapêutico , Docetaxel , Fluoruracila , Humanos , Recidiva Local de Neoplasia , Peplomicina/uso terapêutico , Taxoides/uso terapêutico
4.
Chembiochem ; 19(7): 664-668, 2018 04 04.
Artigo em Inglês | MEDLINE | ID: mdl-29334166

RESUMO

Capillary electrophoresis, coupled with DNA 5' Texas Red labeling, was used to investigate the ability of MNase, FeII peplomycin, and duocarmycin B2 to access the nucleosome. Distinct accessibility patterns of these species to the nucleosome were observed. MNase was completely prevented from approaching the nucleosome core and exhibited a higher site specificity for targeting DNA sites located close to the core region. Intercalation of peplomycin in the nucleosomal core region was highly suppressed, but reaction sites located at the ends of the nucleosomal core remained accessible, which implied flexibility of the core DNA end. Duocarmycin B2 was able to enter and react in the core region, although its alkylating efficiency decreased significantly.


Assuntos
Compostos Ferrosos/química , Indóis/química , Nuclease do Micrococo/química , Nucleossomos/química , Peplomicina/química , DNA/química , Clivagem do DNA/efeitos dos fármacos , Duocarmicinas , Eletroforese Capilar , Pirrolidinonas/química
5.
J Biol Inorg Chem ; 22(7): 1039-1054, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28748309

RESUMO

Bleomycins are a group of glycopeptide antibiotics synthesized by Streptomyces verticillus that are widely used for the treatment of various neoplastic diseases. These antibiotics have the ability to chelate a metal center, mainly Fe(II), and cause site-specific DNA cleavage. Bleomycins are differentiated by their C-terminal regions. Although this antibiotic family is a successful course of treatment for some types of cancers, it is known to cause pulmonary fibrosis. Previous studies have identified that bleomycin-related pulmonary toxicity is linked to the C-terminal region of these drugs. This region has been shown to closely interact with DNA. We examined the binding of Zn(II)peplomycin and Zn(II)bleomycin-A2 to a DNA hairpin of sequence 5'-CCAGTATTTTTACTGG-3', containing the binding site 5'-GT-3', and compared the results with those obtained from our studies of the same MBLMs bound to a DNA hairpin containing the binding site 5'-GC-3'. We provide evidence that the DNA base sequence has a strong impact in the final structure of the drug-target complex.


Assuntos
Antibióticos Antineoplásicos/farmacologia , Bleomicina/farmacologia , DNA/metabolismo , Peplomicina/farmacologia , Zinco/farmacologia , Antibióticos Antineoplásicos/química , Sítios de Ligação , Bleomicina/análogos & derivados , DNA/química , Humanos , Neoplasias/tratamento farmacológico , Neoplasias/metabolismo , Ressonância Magnética Nuclear Biomolecular , Peplomicina/análogos & derivados , Zinco/química
6.
Anticancer Res ; 37(4): 1885-1889, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-28373456

RESUMO

BACKGROUND: Continuous intra-arterial (IA) administration of peplomycin (PEP) through a tumor-feeding artery is one of the most effective treatments for cutaneous squamous cell carcinoma (cSCC) in cosmetic areas. PATIENTS AND METHODS: In order to determine the effective and safe dose of PEP and the curative rate of IA-PEP, we retrospectively investigated a case series of 24 patients with cSCC on the lips who were treated with IA-PEP. RESULTS: IA-PEP reduced the tumor mass in all 24 cases (100%). A complete response occurred in 17 patients (70.8%), and a partial response occurred in seven (29.2%). Moreover, 17 patients (70.8%) were cured, three patients developed cervical lymph node metastasis (12.5%), and four developed local recurrence (16.7%). Three out of the 24 patients developed interstitial pneumonia (12.5%). CONCLUSION: Low-dose IA-PEP administered through a superficial temporal artery was a highly effective treatment that achieved a curative response for 70.8% of patients with cSCC on the lips.


Assuntos
Antibióticos Antineoplásicos/administração & dosagem , Carcinoma de Células Escamosas/tratamento farmacológico , Neoplasias Labiais/tratamento farmacológico , Peplomicina/administração & dosagem , Neoplasias Cutâneas/tratamento farmacológico , Artérias Temporais , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Células Escamosas/patologia , Feminino , Humanos , Infusões Intra-Arteriais , Neoplasias Labiais/patologia , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Prognóstico , Estudos Retrospectivos , Neoplasias Cutâneas/patologia
8.
Dermatology ; 230(3): 250-5, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25678188

RESUMO

BACKGROUND: Continuous intra-arterial administration of peplomycin (PEP) through a tumor-feeding artery using an intravascular indwelling catheter is one of the best treatments for cutaneous squamous cell carcinoma (SCC) on cosmetic areas. Although this reagent is useful for the treatment of SCC, its immunomodulatory effect on the tumor microenvironment is still unknown. OBJECTIVE/METHODS: In this study, we investigated the immunomodulatory effects of PEP on the tumor-infiltrating regulatory T cells and tumor-associated macrophages as well as CD8(+)TIA-1(+) cytotoxic T cells in the lesional skin of 5 patients with SCC on the lips. RESULTS: Our data suggest that, in addition to the direct antitumor effects, PEP decreased immunosuppressive cells and increased cytotoxic T lymphocytes at the tumor sites, which might maintain antitumor immune response against SCC.


Assuntos
Antibióticos Antineoplásicos/administração & dosagem , Carcinoma de Células Escamosas/tratamento farmacológico , Imunomodulação/efeitos dos fármacos , Peplomicina/administração & dosagem , Neoplasias Cutâneas/tratamento farmacológico , Antibióticos Antineoplásicos/farmacologia , Carcinoma de Células Escamosas/imunologia , Humanos , Infusões Intra-Arteriais , Lábio , Macrófagos/efeitos dos fármacos , Neovascularização Patológica , Peplomicina/farmacologia , Neoplasias Cutâneas/imunologia , Linfócitos T Citotóxicos/efeitos dos fármacos , Linfócitos T Citotóxicos/imunologia , Linfócitos T Reguladores/efeitos dos fármacos , Linfócitos T Reguladores/imunologia
9.
Eur J Surg Oncol ; 41(3): 361-7, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25312685

RESUMO

INTRODUCTION: Patients with muscle-invasive bladder cancer (MIBC) often undergo various preoperative treatments to improve survival; however, their efficacy and safety remain unclear. MATERIALS AND METHODS: The anti-tumour effects and adverse events were evaluated in 163 MIBC patients who received systemic chemotherapy (SC, n = 34), intra-arterial chemotherapy (IAC, n = 50), or combined IAC and radiotherapy (IAC + R, n = 79). RESULTS: Pathological complete responses were observed in 17.6%, 22.0%, and 43.0% of patients in the SC, IAC, and IAC + R groups, respectively, with respective 5-year overall survival rates of 42.0%, 46.7%, and 50.3%. Multivariate analysis showed that successful IAC + R protocol administration was a significant predictor for survival (hazard ratio = 0.16, p = 0.028). The incidence of severe adverse events was higher in the IAC + R group (36.7%) than in the SC (9.8%) and IAC groups (16.0%). CONCLUSIONS: IAC + R was useful for patients with MIBC. Successful completion and optimal patient selection were important for this treatment strategy.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células de Transição/terapia , Neoplasias da Bexiga Urinária/terapia , Bexiga Urinária/patologia , Idoso , Idoso de 80 Anos ou mais , Carboplatina/administração & dosagem , Carcinoma de Células de Transição/patologia , Quimiorradioterapia , Quimiorradioterapia Adjuvante , Quimioterapia Adjuvante , Cisplatino/administração & dosagem , Cistectomia , Feminino , Fluoruracila/administração & dosagem , Humanos , Infusões Intra-Arteriais , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Terapia Neoadjuvante/métodos , Invasividade Neoplásica , Tratamentos com Preservação do Órgão , Peplomicina/administração & dosagem , Prognóstico , Resultado do Tratamento , Neoplasias da Bexiga Urinária/patologia
10.
Urologia ; 80(1): 74-9, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23504866

RESUMO

INTRODUCTION: Primary extragonadal germ cell tumors (EGCT) are rare and it is still a matter of debate if they have to be considered as primary extragonadal issues or metastases from a primary testicular neoplasm. We describe two cases of the so-called burned-out seminoma, a primary testicular germ-cell tumor that spontaneously regressed after demonstration of retroperitoneal metastases. CASES PRESENTATION: Two patients (35 and 50 years old, respectively) presented with CT findings of retroperitoneal masses. In both cases physical examination of the testis was not suspicious, and only scrotal ultrasound (SUS) showed parenchymal alterations such as scarring, calcifications and nodular lesions. Left orchiectomy and chemotherapy were then performed in both cases. Currently, they are both free of disease. CONCLUSIONS: Although primary germ cell tumors may be of retroperitoneal origin, the likelihood of metastasis from a testicular primary origin should always be carefully considered in order to avoid misdiagnosis and to apply the best treatment schedule for the patients. Therefore, a testicular ultrasonography is mandatory in patients presenting CT findings of retroperitoneal adenopathy, even if patients are completely asymptomatic and their physical examination appears normal.


Assuntos
Neoplasias Retroperitoneais/secundário , Seminoma/secundário , Neoplasias Testiculares/patologia , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Doenças Assintomáticas , Biomarcadores Tumorais/análise , Neoplasias Ósseas/tratamento farmacológico , Neoplasias Ósseas/secundário , Calcinose/patologia , Humanos , Hidronefrose/diagnóstico por imagem , Hidronefrose/etiologia , Ifosfamida/administração & dosagem , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica , Orquiectomia , Peplomicina/administração & dosagem , Remissão Espontânea , Neoplasias Retroperitoneais/diagnóstico por imagem , Neoplasias Retroperitoneais/tratamento farmacológico , Seminoma/diagnóstico por imagem , Seminoma/tratamento farmacológico , Seminoma/cirurgia , Neoplasias Testiculares/diagnóstico por imagem , Neoplasias Testiculares/cirurgia , Tomografia Computadorizada por Raios X , Ultrassonografia , Bexiga Urinária/diagnóstico por imagem , Bexiga Urinária/patologia , Vincristina/administração & dosagem
11.
Eur J Obstet Gynecol Reprod Biol ; 163(1): 67-70, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-22480411

RESUMO

OBJECTIVE: Levels of 5-FU metabolic or related enzymes, particularly thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD), have been investigated in various cancer types, including uterine cervical cancer. Intratumoral TP levels have been reported to increase in response to several chemotherapeutic agents or irradiation in both xenografts and clinical studies. In cervical cancer, however, only a few studies about changes in TP and DPD expression associated with cancer treatment have been published. We evaluated the effect of chemotherapy and/or irradiation on TP and DPD expression in cervical squamous cell carcinoma. STUDY DESIGN: Of 27 patients in this study, 12 patients underwent neoadjuvant chemotherapy consisting of nedaplatin, ifosfamide, and/or peplomycin followed by radical surgery, and 15 patients underwent radiotherapy (n=8) or chemoradiotherapy with nedaplatin (n=7) as initial treatment. Tumor specimens were obtained from biopsies acquired before treatment and after administration of chemotherapy (2 weeks after the first and second cycles), and after irradiation with 10 Gy, 20 Gy, and 30 Gy. These specimens were used to measure TP and DPD levels by ELISA. RESULTS: In the 12 patients who received neoadjuvant chemotherapy, intratumoral TP and DPD levels did not change. In contrast, in the 15 patients who underwent radiotherapy or chemoradiotherapy with nedaplatin, TP or DPD expression appeared to be slightly increased or decreased, respectively, after irradiation with 20 Gy, and consequently the TP/DPD ratio was significantly higher after irradiation with 20 Gy than before irradiation. CONCLUSIONS: These results suggest a clinical advantage of chemoradiotherapy with capecitabine or doxyfluridine over radiotherapy alone via the elevation of the TP/DPD ratio in cervical squamous cell carcinoma. However, no advantage of combination chemotherapy with these 5-FU derivatives was demonstrated. Therefore, further evaluation with a larger number of patients or with other chemotherapeutic agents is required to confirm these observations.


Assuntos
Carcinoma de Células Escamosas/terapia , Di-Hidrouracila Desidrogenase (NADP)/metabolismo , Timidina Fosforilase/metabolismo , Neoplasias do Colo do Útero/terapia , Adulto , Idoso , Antimetabólitos Antineoplásicos/uso terapêutico , Capecitabina , Quimiorradioterapia , Desoxicitidina/administração & dosagem , Desoxicitidina/análogos & derivados , Di-Hidrouracila Desidrogenase (NADP)/efeitos dos fármacos , Di-Hidrouracila Desidrogenase (NADP)/efeitos da radiação , Feminino , Floxuridina/administração & dosagem , Fluoruracila/administração & dosagem , Fluoruracila/análogos & derivados , Humanos , Ifosfamida/administração & dosagem , Pessoa de Meia-Idade , Terapia Neoadjuvante , Compostos Organoplatínicos/administração & dosagem , Peplomicina/administração & dosagem , Timidina Fosforilase/efeitos dos fármacos , Timidina Fosforilase/efeitos da radiação , Neoplasias do Colo do Útero/enzimologia
12.
J Inorg Biochem ; 111: 50-8, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22484500

RESUMO

The solution structure of Fe(II)-peplomycin was determined from NMR data collected for this molecule. As found previously for Fe(II)- and Co(II)-bound bleomycin; the coordination sphere of the metal is composed of the primary and secondary amines in ß-aminoalanine, the pyrimidine and imidazole rings in the pyrimidinylpropionamide, and ß-hydroxyhistidine moieties, respectively, the amine nitrogen in ß-hydroxyhistidine, and either the carbamoyl group in mannose or a solvent molecule. The two most discussed coordination geometries for the aforementioned ligands in metallo-bleomycins have been tested against the NMR data generated for Fe(II)-peplomycin. The interpretation of the experimental evidence obtained through molecular dynamics indicates that both geometries are equally likely in solution for this compound in the absence of DNA, but arguments are offered to explain why one of these geometries is preferred in the presence of DNA.


Assuntos
Complexos de Coordenação/química , Compostos Ferrosos/química , Ferro/química , Peplomicina/química , Aminas/química , Antibióticos Antineoplásicos/química , Sítios de Ligação , Dissacarídeos/química , Glucose/química , Espectroscopia de Ressonância Magnética/métodos , Manose/química , Modelos Moleculares , Estrutura Molecular , Soluções/química
13.
J Antibiot (Tokyo) ; 64(4): 309-16, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21326254

RESUMO

¹H-NMR spectra of peplomycin (PEP) recorded at 400 and, for the first time, 900 MHz at 2 °C were examined. All the spin systems in the PEP molecule were identified through 2D NMR spectroscopy. The use of NMR spectroscopy allowed the unambiguous assignment of 62 protons, generating 47 non-exchangeable and 15 exchangeable signals. The analysis of the signals observed in 2D-NOE spectra indicates that PEP exhibits an extended conformation at 2 °C. A comparison between the solution conformation of apo-PEP and the solution structure of HOO-Co(III)-PEP indicates that the overall structure of apo-PEP is extended in solution, but exhibiting a conformation of the bithiazole (B)-sulfonium (S) unit similar to that of HOO-Co(III)-PEP. The present investigation represents the initial stage of an NMR study of the solution conformation and dynamics of PEP, its derivatives, its metal complexes and the interactions of metallo-PEPs with their target DNA.


Assuntos
Antibióticos Antineoplásicos/química , DNA/metabolismo , Espectroscopia de Ressonância Magnética/métodos , Metais/química , Peplomicina/química , Soluções
14.
Histochem Cell Biol ; 135(1): 93-101, 2011 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21153656

RESUMO

Peplomycin (PEP), an anti-tumor antibiotic related structurally to bleomycin, is widely used, especially for squamous cell carcinoma but shows renal toxicity. We prepared monoclonal antibodies (mAbs) against N-(γ-maleimidobutyryloxy)succinimide-conjugated PEP. The mAbs were monospecific for PEP, but did not react with bleomycin and other anticancer antibiotics. The mAbs enabled us to develop an immunocytochemical (ICC) method for detecting the uptake of PEP in the rat kidney. Two hours after a single i.v. administration of PEP, ICC revealed immunostaining for PEP in irregularly shaped cytoplasmic granules of the proximal tubules in which the microvilli were also stained. Also, staining occurred in the distal tubules and collecting ducts, in both of which we observed scattered swollen cells, reminiscent of necrotic cells, in which both the nuclei and cytoplasm reacted strongly with the antibody. Twenty-four hours after injection, PEP in the proximal tubules completely vanished, but yet significant amounts of PEP remained in both the distal tubules and collecting ducts. Distribution patterns of PEP in cells of the kidneys resembled, in some ways, those of our recent ICC studies for an organic cation aminoglycoside antibiotic gentamicin. This ICC suggests that PEP taken up in the proximal tubule cells is localized in the lysosomes, and organic cation transporters and bleomycin hydrolase might be involved in entrance and/or disappearance of PEP in this cell type. Furthermore, the distal tubules and collecting ducts may be the sites readily affected by some chemotherapeutic agents.


Assuntos
Antibióticos Antineoplásicos/metabolismo , Anticorpos Monoclonais , Rim/metabolismo , Peplomicina/metabolismo , Animais , Ensaio de Imunoadsorção Enzimática , Humanos , Imuno-Histoquímica , Masculino , Camundongos , Ratos , Ratos Wistar
15.
Oral Oncol ; 45(9): 794-7, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19200774

RESUMO

The presence or absence of metastasis bears an important influence on the prognosis of head and neck cancer patients. Neoadjuvant chemotherapy has become widely employed as an initial treatment. However, the actual effectiveness of neoadjuvant chemotherapy on metastasis is still unestablished. Therefore, using an orthotopic implantation model in which cervical lymph node metastasis of oral squamous cell carcinoma can be reproduced, we investigated the inhibitory effect of neoadjuvant chemotherapy on metastasis. A highly invasive and metastatic human oral squamous cell carcinoma cell line, OSC-19 cells, was implanted into the tongues of nude mice. After implantation, the mice were divided into four groups: S (surgery), C+S (preoperative chemotherapy+surgery), S+C (surgery+postoperative chemotherapy), and a control (nontreatment) groups. The treatment (tumor resection or chemotherapy) was started 7 days postimplantation. The effects of each treatment on cervical lymph node metastasis were investigated by examining the rate of lymph node metastasis formation at 28 days postimplantation. In the control group, five of the 11 mice died of cachexia before the end of the experiment. However, all mice in the S, C+S, and S+C groups survived until 28 days after implantation. The cervical lymph node metastasis rates were 81.8% in S, 18.1% in C+S, 63.6% in S+C, and 100% in control groups. Thus, metastasis to the cervical lymph node was markedly inhibited by the combination of neoadjuvant chemotherapy and tumor resection. The findings of this study indicate that neoadjuvant chemotherapy is effective for inhibiting metastasis, and that it is necessary to begin chemotherapy as early as possible to achieve an inhibitory effect on metastasis. Considering these effects, if anticancer drugs are used, better therapeutic results can be expected.


Assuntos
Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/secundário , Neoplasias da Língua/tratamento farmacológico , Animais , Antibióticos Antineoplásicos/uso terapêutico , Antineoplásicos/uso terapêutico , Carcinoma de Células Escamosas/cirurgia , Cisplatino/uso terapêutico , Modelos Animais de Doenças , Feminino , Humanos , Metástase Linfática , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Pescoço , Terapia Neoadjuvante/métodos , Peplomicina/uso terapêutico , Neoplasias da Língua/patologia , Neoplasias da Língua/cirurgia , Resultado do Tratamento
16.
Ai Zheng ; 27(9): 956-61, 2008 Sep.
Artigo em Chinês | MEDLINE | ID: mdl-18799035

RESUMO

BACKGROUND & OBJECTIVE: Cervical adenosquamous carcinoma is a special histological type of cervical carcinoma. Its clinic-pathologic characteristics and prognostic factors have seldom been reported. This study was to explore the clinic-pathologic characteristics and prognostic factors of cervical adenosquamous carcinoma. METHODS: Clinical data of 83 pathologically confirmed adenosquamous cervical carcinoma patients in Sun Yat-sen University Cancer Center from Nov. 1982 to May 2006 were analyzed. RESULTS: The median overall survival (OS) of 83 patients was 47 months and the median disease-free survival was 43 months. The 5-year survival rate was 74.0%, and the recurrence rate (DFS) was 30.1% (25/83). The median OS and DFS were 58 months and 54 months versus 37 months and 21 months in patients with or without lymph node metastasis (P=0.005, P<0.001). The median DFS was 47 months and 16 months for patients with the tumor diameter >4 or < or =4 cm (P=0.015), respectively. Lymph node metastasis was correlated to FIGO stage, tumor diameter and invasion depth. The recurrence rate of patients with ovarian preservation was 33.3% (3/9). CONCLUSIONS: Lymph node metastasis is an independent risk factor for prognosis in cervical adenosquamous carcinoma. Adjunctive postoperative irradiation would improve the OS and DFS. Tumor diameter greater than 4cm is an independent prognostic risk of DFS. The impact of ovarian preservation on prognosis is unclear.


Assuntos
Carcinoma Adenoescamoso/terapia , Histerectomia/métodos , Neoplasias do Colo do Útero/terapia , Aclarubicina/uso terapêutico , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Braquiterapia , Carcinoma Adenoescamoso/patologia , Quimioterapia Adjuvante , Cisplatino/uso terapêutico , Intervalo Livre de Doença , Feminino , Seguimentos , Humanos , Metástase Linfática , Pessoa de Meia-Idade , Invasividade Neoplásica , Recidiva Local de Neoplasia , Estadiamento de Neoplasias , Peplomicina/uso terapêutico , Prognóstico , Modelos de Riscos Proporcionais , Radioterapia Adjuvante , Taxa de Sobrevida , Carga Tumoral , Neoplasias do Colo do Útero/patologia
17.
Anticancer Res ; 28(4B): 2197-204, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18751395

RESUMO

The antitumor antibiotic peplomycin showed higher cytostatic antiproliferative effect on five cultured human oral squamous cell carcinoma (OSCC) cell lines (HSC-2, HSC-3, HSC-4, Ca9-22 and NA), as compared with three human oral normal cells (gingival fibroblast HGF, pulp cell HPC and periodontal ligament fibroblast HPLF). Although the antiproliferative activity of peplomycin declined with increasing cell density, peplomycin showed tumor-specific cytotoxicity at any cell density. The five OSCC cell lines showed considerable differences in sensitivity against peplomycin; the HSC-2 cells were the most sensitive, followed by the NA, HSC-3, Ca9-22 and HSC-4 cells. Peplomycin did not induce internucleosomal DNA fragmentation in any of the five OSCC cell lines, and only slightly modified caspase-3, -8 and -9 activities in the HSC-2, Ca9-22 and NA cell lines. Electron microscopy revealed that peplomycin induced the vacuolation of mitochondria accompanying electron lucent matrices lacking cristae and the enlargement of the endoplasmic reticulum in the HSC-2 cells. These data suggest that the anti-proliferative effect of peplomycin is time-dependent, and therefore prolonged treatment with peplomycin in combination with cytotoxic chemotherapeutic agents may induce greater cytotoxic action.


Assuntos
Antibióticos Antineoplásicos/farmacologia , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/patologia , Neoplasias Bucais/tratamento farmacológico , Neoplasias Bucais/patologia , Peplomicina/farmacologia , Carcinoma de Células Escamosas/ultraestrutura , Morte Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Fibroblastos/citologia , Fibroblastos/efeitos dos fármacos , Humanos , Microscopia Eletrônica , Neoplasias Bucais/ultraestrutura
18.
Acta Oncol ; 47(3): 434-41, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18348003

RESUMO

The purpose of this study was to clarify outcome for concurrent chemoradiation (CT-RT) in locally advanced cervix cancer in Japan. This is a non-randomized retrospective analysis of 226 patients treated with definitive CT-RT or radiotherapy alone (RT alone) in nine institutions between 2001 and 2003. External irradiation consisted of whole pelvic irradiation and pelvic side wall boost irradiation, using a central shield during the latter half of the treatment with the anteroposterior parallel opposing technique. The external beam irradiation was performed with 1.8 or 2 Gy per fraction. High-dose-rate intracavitary brachytherapy (HDR) was performed in all cases. In chemotherapy, platinum based drugs were used alone or in combination with other drugs such as 5FU. Grade of late complications was scaled retrospectively with CTCv2.0. Overall survival rate at 50 months of stage Ib, II and III, IV was 82% and 66% in CR-RT and 81% and 43% in R alone, respectively. Disease-free survival rate at 50 months of stage Ib, II and III, IV was 74% and 59% in CR-RT and 76% and 52% in R alone, respectively. There was no significant difference between CT-RT and RT for overall survival and disease free survival. Univariate analysis suggested that loco-regional control was better with CT-RT, but multivariate analysis could not confirm this finding. Compared to RT alone, CT-RT caused significantly more acute and late complications. Thus, late complication (grade 3-4) free survival rate at 50 month was 69% for CT-RT and 86% for RT alone (p<0.01). The therapeutic window with concomitant radiochemotherapy and HDR brachytherapy may be narrow, necessitating a close control of dose volume parameters and adherence to systems for dose prescription.


Assuntos
Braquiterapia , Carcinoma de Células Escamosas/radioterapia , Neoplasias do Colo do Útero/radioterapia , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/patologia , Adenocarcinoma/radioterapia , Adulto , Idoso , Antineoplásicos Alquilantes/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Braquiterapia/efeitos adversos , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/patologia , Quimioterapia Adjuvante , Terapia Combinada , Intervalo Livre de Doença , Feminino , Fluoruracila/administração & dosagem , Humanos , Irradiação Linfática , Pessoa de Meia-Idade , Mitomicina/administração & dosagem , Compostos Organoplatínicos/administração & dosagem , Compostos Organoplatínicos/uso terapêutico , Peplomicina/administração & dosagem , Dosagem Radioterapêutica , Estudos Retrospectivos , Análise de Sobrevida , Neoplasias do Colo do Útero/tratamento farmacológico , Neoplasias do Colo do Útero/patologia , Vincristina/administração & dosagem
19.
Eur J Gynaecol Oncol ; 28(4): 273-7, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17713091

RESUMO

PURPOSE OF INVESTIGATION: The study was performed to examine how bleomycin (BLM) and peplomycin (PEM) should be effectively used in radiotherapy for cervical squamous cancer patients. METHODS: The effects of BLM on radiosensitivity and the effects of radiation on the sensitivity to BLM of cancer cells were investigated using the radiosensitive human cervical squamous cell carcinoma cell line ME180. RESULTS: BLM treatment did not affect radiosensitivity. However, irradiation significantly reduced cell BLM sensitivity in a dose-dependent manner. There was no significant difference in BLM sensitivity and PEM sensitivity between cells concurrently irradiated and those treated with BLM or PEM 8 h before or 8 h after irradiation. CONCLUSION: Since sensitivity to BLM is reduced during irradiation, BLM should be administered to cervical cancer patients as an adjuvant chemotherapeutic drug after completion of radiotherapy.


Assuntos
Antibióticos Antineoplásicos/farmacologia , Bleomicina/farmacologia , Neoplasias de Células Escamosas/tratamento farmacológico , Neoplasias de Células Escamosas/radioterapia , Neoplasias do Colo do Útero/tratamento farmacológico , Neoplasias do Colo do Útero/radioterapia , Linhagem Celular Tumoral , Quimioterapia Adjuvante/métodos , Terapia Combinada/métodos , Feminino , Humanos , Peplomicina/farmacologia , Radiossensibilizantes
20.
J Neurosurg ; 106(3): 488-94, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17367075

RESUMO

The authors describe the case of a patient with a glioblastoma multiforme who showed remarkably good response to chemotherapy. A genetic analysis using comparative genomic hybridization (CGH) revealed that the tumor had a gain on the q arm of chromosome 1 (1q). Using CGH for a series of genetic analyses of more than 180 patients with gliomas, six were found to have a demonstrated 1q gain. Although the tumors in all six of these cases were histopathologically diagnosed as high-grade gliomas, compared with other malignant gliomas they demonstrated a good prognosis because of their favorable chemotherapeutic sensitivity. In immunohistochemical tests, most of the tumor cells in these cases were negative for O6-methylguanine-DNA methyltransferase, which antagonizes the effect of DNA-alkylating chemotherapeutic agents. The authors believed that a gain of 1q could be produced through the genetic events that cause loss of 1p, because these chromosomal aberrations have an imbalance of DNA copy number in common (1p < 1q). A gain of 1q is an infrequent chromosomal aberration and its clinical importance should be investigated in a larger study; however, patients with malignant gliomas demonstrating a 1q gain possibly show longer survival and good response to chemotherapy similar to patients with tumors demonstrating 1p loss. The importance of using genetic analysis for gliomas is emphasized in this report because it may help in selecting cases responsive to chemotherapy and because appropriate treatment for these patients will lead to progress in the treatment of malignant gliomas.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/genética , Aberrações Cromossômicas , Cromossomos Humanos Par 1/genética , Glioblastoma/tratamento farmacológico , Glioblastoma/genética , Idoso , Neoplasias Encefálicas/patologia , Glioblastoma/patologia , Humanos , Masculino , Nimustina/uso terapêutico , Peplomicina/uso terapêutico , Resultado do Tratamento , Vincristina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...